Cost-effectiveness of HPV Vaccines in Singapore
Author Information
Author(s): Lee Vernon J, Tay Sun Kuie, Teoh Yee Leong, Tok Mei Yin
Primary Institution: National University of Singapore
Hypothesis
How cost-effective are the bivalent and quadrivalent HPV vaccines in preventing cervical cancer in Singapore?
Conclusion
HPV vaccination is a cost-effective strategy and should be considered to reduce the impact of HPV infection.
Supporting Evidence
- 229 cervical cancer cases occurred over the cohort's lifetime without vaccination.
- The quadrivalent vaccine reduced cancers by 176 with an ICER of SGD$12,866 per life-year saved.
- The bivalent vaccine prevented 197 cancers with an ICER of SGD$12,827 per life-year saved.
- The quadrivalent vaccine dominated the bivalent vaccine due to additional QALY effects from genital warts reduction.
Takeaway
Getting vaccinated against HPV can help prevent cervical cancer and is a smart use of healthcare money.
Methodology
A Markov state-transition model was developed to predict HPV infection, cancer incidence, mortality, and costs.
Limitations
The study does not account for herd immunity effects or the dynamics of viral transmission.
Participant Demographics
Hypothetical cohort of 12-year-old females in Singapore.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website